Novel Hybrid and Nanocomposite Materials for Biomedical Applications

用于生物医学应用的新型混合和纳米复合材料

• 批准号: 239099-2012
• 负责人: Rizkalla, Amin
• 金额: $ 1.46万
• 依托单位: University of Western Ontario
• 依托单位国家: 加拿大
• 项目类别: Discovery Grants Program - Individual
• 财政年份: 2016
• 资助国家: 加拿大
• 起止时间: 2016-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=594228
• 关键词: Novel; Hybrid; Nanocomposite; Materials; Biomedical

The rise in life expectancy in developed countries has led to an increase in age-related skeletal diseases such as osteoarthritis and osteoporosis with corresponding increase in demand for materials that can replace and integrate with bone. In addition, over 2.2 million patients per year worldwide undergo surgery for skeletal trauma or tumor resection. The gold standard for bone repair is the autograft. However, limited tissue availability and morbidity at the extraction site have resulted in a high interest in artificial materials for bone replacement and regeneration. Over the next 5 years, the research program will focus on developing: 1) novel bioactive glass and biodegradable natural and synthetic polymer hybrids; 2) sol-gel-hydrothermal derived glass-ceramic nanostructures for bone regeneration; 3) bioactive and antimicrobial coatings for titanium implants that will help enhance the interfacial bond with bone; and 4) novel fast setting and injectable bioactive bone cements for craniofacial reconstruction. The main objective is to train well rounded graduates in the field of bone tissue engineering and regenerative medicine. The overall program will provide training for six (6) PhD students exposing them to cutting edge research in biomaterials synthesis and characterization techniques. Trainees will also become skilled in the development of bioassays. Upon graduation, these students will take leadership roles in bringing biotechnology from the laboratory to the marketplace and clinic. The success of this research is expected to result in significant technology development for applications in regenerative medicine and economical benefit to Canada.

发达国家预期寿命的提高导致骨关节炎和骨质疏松症等与年龄相关的骨骼疾病增加，对可替代和与骨骼融合的材料的需求也相应增加。此外，全球每年有超过 220 万名患者接受骨骼创伤或肿瘤切除手术。骨修复的黄金标准是自体移植。然而，有限的组织可用性和提取部位的发病率导致人们对用于骨替代和再生的人造材料产生了浓厚的兴趣。未来5年，该研究计划将重点开发：1）新型生物活性玻璃以及可生物降解的天然和合成聚合物混合物； 2）溶胶-凝胶-水热法衍生的用于骨再生的微晶玻璃纳米结构； 3）钛植入物的生物活性和抗菌涂层，有助于增强与骨的界面结合； 4）用于颅面重建的新型快速凝固和可注射生物活性骨水泥。主要目标是培养骨组织工程和再生医学领域全面发展的毕业生。整个计划将为六 (6) 名博士生提供培训，让他们接触生物材料合成和表征技术的前沿研究。学员还将熟练掌握生物测定的开发。毕业后，这些学生将在将生物技术从实验室推向市场和诊所方面发挥领导作用。这项研究的成功预计将为再生医学应用带来重大技术发展，并为加拿大带来经济效益。